BlackRock Fund Advisors recently announced the acquisition of new stake in Halozyme Therapeutics Inc. (NASDAQ:HALO). The institutional investor has increased its shareholding in the Healthcare company by 0.24% to 15.02 million shares with purchase of 35885.0 shares. This fresh investment now brings its stake to 11.10% valued currently at $482.56 million. In addition, Macquarie Investment Management B raised its holdings by 51679.0 to 2.61 million shares. And Geode Capital Management LLC has lifted its position by 1.54% or 38233.0 shares – to 2.52 million shares.
With over 1.78 million Halozyme Therapeutics Inc. (HALO) shares trading Monday and a closing price of $35.00 on the day, the dollar volume was approximately $62.29 million. The shares have shown a negative half year performance of -33.66% and its price on 05/22/23 gained nearly 3.34%. Currently, there are 135.03M common shares owned by the public and among those 130.34M shares have been available to trade.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 11 analysts who have offered their price forecasts for HALO have a consensus price objective of $49.60. The analysts have set the share’s price value over the next 12 months at a high of $66.00 and a low of $26.00. The average price target is 29.05% above its recent price level and a downside to the estimated low will see the stock lose -34.62% over that period. But an upside of 46.97% will see the stock hit the forecast high price target while median target price for the stock is $50.00.
Insiders at the company have transacted a total of 83 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 31 of these insider trades were purchases, accounting for 305,714 shares. Insider sales of the common stock occurred on 52 occasions, with total insider shares sold totaling 352,667 shares.
The top 3 mutual fund holders in Halozyme Therapeutics Inc. are iShares Core S&P Mid Cap ETF, Vanguard Total Stock Market ETF, and Vanguard Small Cap Index Fund. iShares Core S&P Mid Cap ETF owns 4.22 million shares of the company’s stock, all valued at over $135.57 million. The company bought an additional 15072.0 shares recently to bring their total holdings to about 3.12% of the shares outstanding. Vanguard Total Stock Market ETF bought 40534.0 shares to see its total holdings expand to 4.19 million shares valued at over $134.74 million and representing 3.10% of the shares outstanding. Vanguard Small Cap Index Fund bought 18514.0 shares to bring its total holdings to over 3.54 million shares at a value of $113.82 million. Vanguard Small Cap Index Fund now owns shares totaling to 2.62% of the shares outstanding.
Shares of Halozyme Therapeutics Inc. (NASDAQ: HALO) opened at $34.11, up $0.24 from a prior closing price of $33.87. However, the script later moved the day high at 35.26, up 3.34%. The company’s stock has a 5-day price change of 3.24% and -29.52% over the past three months. HALO shares are trading -38.49% year to date (YTD), with the 12-month market performance down to -20.16% lower. It has a 12-month low price of $29.85 and touched a high of $59.46 over the same period. HALO has an average intraday trading volume of 1.65 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.33%, -0.20%, and -22.18% respectively.
Institutional ownership of Halozyme Therapeutics Inc. (NASDAQ: HALO) shares accounts for 97.66% of the company’s 135.03M shares outstanding. Mutual fund holders own 32.31%, while other institutional holders and individual stakeholders account for 56.77% and 17.77% respectively.
It has a market capitalization of $4.53B and a beta (3y monthly) value of 1.21. The stock’s trailing 12-month PE ratio is 26.86, while the earnings-per-share (ttm) stands at $1.30. The company has a PEG of 1.03 and a Quick Ratio of 5.50 with the debt-to-equity ratio at 22.68. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.42% over the week and 3.81% over the month.
Analysts forecast that Halozyme Therapeutics Inc. (HALO) will achieve an EPS of $0.63 for the current quarter, $0.73 for the next quarter and $3.66 for 2024. The lowest estimate earnings-per-share for the quarter is $0.57 while analysts give the company a high EPS estimate of $0.66. Comparatively, EPS for the current quarter was $0.53 a year ago. Earnings per share for the fiscal year are expected to decrease by -47.60%, and 39.82% over the next financial year. EPS should grow at an annualized rate of 26.00% over the next five years, compared to 26.00% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 11 brokerage firm advisors rate Halozyme Therapeutics Inc. (HALO) as a “Moderate Buy” at a consensus score of 2.40. Specifically, 9 Wall Street analysts polled rate the stock as a buy, while 1 of the 11 advise that investors “hold,” and 1 rated it as a “Sell.”
